In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors

Molecular Therapy

Volumn 3, Issue 6, 2001, Pages 850-856

  Stein, Colleen S ^a   Kang, Yubin ^a   Sauter, Sybille L ^b   Townsend, Kay ^b   Staber, Patrick ^a   Derksen, Todd A ^a   Martins, Inês ^a   Qian, Jiahua ^c   Davidson, Beverly L ^a   McCray Jr , Paul B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Gene therapy; Hemophilia A; Lentiviral vector; Mucopolysaccharidosis; glucuronidase

Indexed keywords

BETA GLUCURONIDASE; BLOOD CLOTTING FACTOR 8; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; ENZYME ACTIVITY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMOPHILIA A; LENTIVIRINAE; LIVER; LIVER CELL; LYSOSOME; MALE; MOUSE; MOUSE STRAIN; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; SPLEEN; SURVIVAL; TARGET ORGAN; TRANSGENE; VIRUS REPLICATION;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRUS;

EID: 0034960875     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0325     Document Type: Article

References (32)

1. Advances toward gene therapy for hemophilia at the millennium
2. The mucopolysaccharidoses
3. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation
4. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer
5. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells
6. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts
7. Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission
8. Minimal requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors
9. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
10. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect
11. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
12. Efficient lentiviral transduction of liver requires cell cycling in vivo
13. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII
14. Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer
15. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes
16. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
17. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
18. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies
19. Bone marrow stromal cell-mediated gene therapy for hemophilia A: In vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648
20. A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII
21. Extensive β-glucuronidase activity in murine CNS after adenovirus mediated gene transfer to brain
22. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice
23. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade
24. Hemophilia A
25. Cross-correction of β-glucuronidase deficiency by retroviral vector-mediated gene transfer
26. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts
27. Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice
28. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences
29. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
30. Liver regeneration
31. 1-antitrypsin in vivo
32. Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy